SVB Leerink Increases Axsome Therapeutics (NASDAQ:AXSM) Price Target to $85.00

Axsome Therapeutics (NASDAQ:AXSMGet Rating) had its price target raised by SVB Leerink from $65.00 to $85.00 in a research report report published on Tuesday, Stock Target Advisor reports. The firm currently has an outperform rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. HC Wainwright reissued a buy rating and issued a $210.00 price target on shares of Axsome Therapeutics in a research note on Tuesday, October 4th. Guggenheim lifted their target price on shares of Axsome Therapeutics from $72.00 to $80.00 and gave the stock a buy rating in a research note on Friday, November 11th. Cowen lowered their target price on shares of Axsome Therapeutics to $125.00 in a research note on Wednesday, October 5th. Loop Capital assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, November 1st. They set a buy rating and a $95.00 target price on the stock. Finally, Morgan Stanley lowered their target price on shares of Axsome Therapeutics from $74.00 to $73.00 and set an equal weight rating on the stock in a research note on Tuesday, November 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $111.55.

Axsome Therapeutics Stock Performance

AXSM opened at $71.97 on Tuesday. Axsome Therapeutics has a 12-month low of $20.63 and a 12-month high of $79.68. The company has a current ratio of 4.19, a quick ratio of 4.15 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $3.13 billion, a PE ratio of -17.73 and a beta of 1.75. The firm has a 50 day moving average of $51.32 and a two-hundred day moving average of $45.27.

Institutional Trading of Axsome Therapeutics

Large investors have recently made changes to their positions in the stock. Fairmount Funds Management LLC boosted its stake in Axsome Therapeutics by 402.4% in the 1st quarter. Fairmount Funds Management LLC now owns 942,571 shares of the company’s stock worth $39,013,000 after buying an additional 754,973 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in Axsome Therapeutics by 1,379.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 617,900 shares of the company’s stock worth $27,571,000 after purchasing an additional 576,125 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Axsome Therapeutics by 549.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 377,337 shares of the company’s stock worth $14,452,000 after acquiring an additional 319,200 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Axsome Therapeutics by 11.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,111,500 shares of the company’s stock worth $138,835,000 after acquiring an additional 309,362 shares in the last quarter. Finally, PFM Health Sciences LP boosted its position in Axsome Therapeutics by 22.0% during the 3rd quarter. PFM Health Sciences LP now owns 1,659,733 shares of the company’s stock valued at $74,057,000 after purchasing an additional 299,137 shares during the period. Institutional investors and hedge funds own 54.96% of the company’s stock.

Axsome Therapeutics Company Profile

(Get Rating)

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation.

See Also

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.